Journal ArticleDOI
Ketoconazole and the liver.
Reads0
Chats0
About:
This article is published in The Lancet.The article was published on 1982-04-10. It has received 25 citations till now. The article focuses on the topics: Ketoconazole.read more
Citations
More filters
Book ChapterDOI
Clinical Pharmacology of Systemic Antifungal Agents: A Comprehensive Review of Agents in Clinical Use, Current Investigational Compounds, and Putative Targets for Antifungal Drug Development
Journal ArticleDOI
Azole resistance in Candida albicans
TL;DR: Two isolates of Candida albicans from chronic mucocutaneous candidosis patients who initially responded to ketoconazole treatment but who later relapsed, have shown an abnormal response to ketconazole in four out of five systems in vitro and in three animal models of vaginal or systemic infection.
Journal ArticleDOI
Clinical Pharmacokinetics of Systemic Antifungal Drugs
T. K. Daneshmend,D. W. Warnock +1 more
TL;DR: The currently available drugs for the treatment of systemic fungal infections are amphotericin B, flucytosine, miconazole and ketoconazole, all of which have to be given intravenously for treatment of deep mycoses.
Journal ArticleDOI
Ketoconazole. Mechanism of action, spectrum of activity, pharmacokinetics, drug interactions, adverse reactions and therapeutic use
TL;DR: Ketoconazole is a well‐tolerated oral antifungal agent with a broad spectrum of activity in vitro, but in vitro testing has not yet been correlated to in vivo results, and many variables that can alter in vitro test results have been identified.
Journal ArticleDOI
Ketoconazole-associated hepatic injury. A clinicopathological study of 55 cases.
TL;DR: The mechanism of ketoconazole-induced hepatic injury seems to be based on metabolic idiosyncrasy although it is not excluded that in some patients an immunoallergic mechanism is causative.
References
More filters
Journal ArticleDOI
Long-term therapy of chronic mucocutaneous candidiasis with ketoconazole: Experience with twenty-one patients
TL;DR: It is concluded that ketoconazole is an effective and well-tolerated drug for the treatment of the infectious component of chronic mucocutaneous candidiasis.
Journal ArticleDOI
Treatment of Chronic Mucocutaneous Candidiasis with Ketoconazole: A Controlled Clinical Trial
TL;DR: Oral ketoconazole is an effective treatment for chronic mucocutaneous candidiasis and Hepatitis developed in one patient after 6 months of treatment but proved to be mild and reversible.